XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.22.1

REVENUE (Tables) | 6 Months Ended
--- | ---
Apr. 30, 2022
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended April 30,
| 2022 |  | 2021
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 321 |  |  | $ | 137 |  |  | $ | 201 |  |  | $ | 659 |  |  | $ | 296 |  |  | $ | 122 |  |  | $ | 163 |  |  | $ | 581 |
Europe | 216 |  |  | 97 |  |  | 110 |  |  | 423 |  |  | 214 |  |  | 95 |  |  | 106 |  |  | 415 |
Asia Pacific | 359 |  |  | 119 |  |  | 47 |  |  | 525 |  |  | 371 |  |  | 112 |  |  | 46 |  |  | 529 |
Total | $ | 896 |  |  | $ | 353 |  |  | $ | 358 |  |  | $ | 1,607 |  |  | $ | 881 |  |  | $ | 329 |  |  | $ | 315 |  |  | $ | 1,525 |
| Six Months Ended April 30,
| 2022 |  | 2021
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 638 |  |  | $ | 269 |  |  | $ | 389 |  |  | $ | 1,296 |  |  | $ | 575 |  |  | $ | 246 |  |  | $ | 315 |  |  | $ | 1,136 |
Europe | 468 |  |  | 195 |  |  | 211 |  |  | 874 |  |  | 459 |  |  | 187 |  |  | 206 |  |  | 852 |
Asia Pacific | 766 |  |  | 248 |  |  | 97 |  |  | 1,111 |  |  | 770 |  |  | 227 |  |  | 88 |  |  | 1,085 |
Total | $ | 1,872 |  |  | $ | 712 |  |  | $ | 697 |  |  | $ | 3,281 |  |  | $ | 1,804 |  |  | $ | 660 |  |  | $ | 609 |  |  | $ | 3,073 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Six Months Ended
| April 30, |  | April 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 589 |  |  | $ | 531 |  |  | $ | 1,191 |  |  | $ | 1,052 |
Chemical and Energy | 335 |  |  | 314 |  |  | 708 |  |  | 642 |
Diagnostics and Clinical | 241 |  |  | 233 |  |  | 484 |  |  | 449 |
Food | 137 |  |  | 144 |  |  | 295 |  |  | 306 |
Academia and Government | 146 |  |  | 143 |  |  | 287 |  |  | 285 |
Environmental and Forensics | 159 |  |  | 160 |  |  | 316 |  |  | 339 |
Total | $ | 1,607 |  |  | $ | 1,525 |  |  | $ | 3,281 |  |  | $ | 3,073 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 646 |  |  | $ | 632 |  |  | $ | 1,337 |  |  | $ | 1,313 |
Non-instrumentation and other | 961 |  |  | 893 |  |  | 1,944 |  |  | 1,760 |
Total | $ | 1,607 |  |  | $ | 1,525 |  |  | $ | 3,281 |  |  | $ | 3,073 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2022:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2021 |  | $ | 519 |
Net revenue deferred in the period |  | 332 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (283) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 48 |
Currency translation and other adjustments |  | (19) |
Ending balance as of April 30, 2022 |  | $ | 597 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration